ClinicalTrials.gg
CompletedNCT02087904Updated Aug 28, 2019Results posted

A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis

A Phase 2 interventional study of ABT-981 and Placebo in Knee Osteoarthritis and Medial Compartment Knee Osteoarthritis, sponsored by AbbVie. Completed. Open to participants aged 35 Years to 74 Years. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
35 Years to 74 Years
Sex
All
01

Study summary

A Phase 2a, multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic effect of ABT-981 in patients with symptomatic, radiographic, and inflammatory knee osteoarthritis.

02

Conditions studied

  • Knee Osteoarthritis
  • Medial Compartment Knee Osteoarthritis

Keywords

  • Osteoarthritis
  • Synovitis
  • Knee
  • Pain
03

In context

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

This study's enrollment of 350 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Radiographic knee osteoarthritis with Kellgren-Lawrence Grade 2 or 3
  2. (BMI) 18-34 kg/m2
  3. One or more clinical signs and symptoms of active inflammation in the index knee

Exclusion criteria

Exclusion Criteria:

  1. History of allergic reaction to any constituents of the study drug, or to any Immunoglobulin G (IgG)-containing product
  2. History of anaphylactic reaction to any agent
  3. Significant trauma or surgery to the index knee
  4. Severe knee malalignment
  5. Any uncontrolled medical illness or an unstable treatment or therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    ABT-981 low dose

    25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)

    Biological: ABT-981

  • Experimental
    ABT-981 medium dose

    100 mg ABT-981 SC E2W

    Biological: ABT-981

  • Experimental
    ABT-981 high dose

    200 mg ABT-981 SC E2W

    Biological: ABT-981

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalABT-981

    Also known as: Lutikizumab

  • OtherPlacebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16

    The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 16

  2. Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26

    Change in synovitis of the index knee was evaluated using quantitative magnetic resonance imaging (MRI) measurements. MRI quantitative synovitis of the index knee was defined by mean synovial membrane thickness.

    Time frame: Baseline, Week 26

  3. Change From Baseline in Effusion Volume of the Index Knee at Week 26

    Time frame: Baseline, Week 26

  4. Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26

    Semi-quantitative synovitis/effusion volume WORMS scores were scored as normal (0), \< 33% of maximum estimated distention (1), 33% - 66% of maximum estimated distention (2), or \> 66% of maximum estimated distention (3).

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16

    The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 16

  2. Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26

    The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 26

  3. Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52

    The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 52

  4. Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26

    The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 26

  5. Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52

    The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 52

  6. Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26

    BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).

    Time frame: Baseline, Week 26

  7. Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52

    BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).

    Time frame: Baseline, Week 52

  8. Change From Baseline in Index Knee Intermittent and Constant Osteoarthritis Pain (ICOAP) Scores at Week 16

    The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).

    Time frame: Baseline, Week 16

  9. Change From Baseline in Index Knee ICOAP Scores at Week 26

    The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).

    Time frame: Baseline, Week 26

  10. Change From Baseline in Index Knee ICOAP Scores at Week 52

    The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).

    Time frame: Baseline, Week 52

  11. Change From Baseline In Index Knee Pain Intensity at Week 16

    The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.

    Time frame: Baseline, Week 16

  12. Change From Baseline In Index Knee Pain Intensity at Week 26

    The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.

    Time frame: Baseline, Week 26

  13. Change From Baseline In Index Knee Pain Intensity at Week 52

    The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.

    Time frame: Baseline, Week 52

  14. Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16

    The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.

    Time frame: Baseline, Week 16

  15. Change From Baseline in PGA of Arthritis of the Index Knee at Week 26

    The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.

    Time frame: Baseline, Week 26

  16. Change From Baseline in PGA of Arthritis of the Index Knee at Week 52

    The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.

    Time frame: Baseline, Week 52

  17. Change From Baseline in Cartilage Volume of the Index Knee at Week 26

    Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.

    Time frame: Baseline, Week 26

  18. Change From Baseline in Cartilage Volume of the Index Knee at Week 52

    Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.

    Time frame: Baseline, Week 52

  19. Change From Baseline in Cartilage Thickness of the Index Knee at Week 26

    Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.

    Time frame: Baseline, Week 26

  20. Change From Baseline in Cartilage Thickness of the Index Knee at Week 52

    Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.

    Time frame: Baseline, Week 52

  21. Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16

    Percentage of participants classified as OMERACT-OARSI responders at Week 16. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.

    Time frame: Week 16

  22. Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26

    Percentage of participants classified as OMERACT-OARSI responders at Week 26. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.

    Time frame: Week 26

  23. Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52

    Percentage of participants classified as OMERACT-OARSI responders at Week 52. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.

    Time frame: Week 52

07

Results

Posted Aug 28, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Started85898789
Completed60706564
Not completed25192225
Withdrew: Did not receive study drug0021
Withdrew: Adverse event84412
Withdrew: Lack of efficacy3632
Withdrew: Other6244
Withdrew: Withdrawal by subject8374
Withdrew: Lost to follow-up0422

Outcome measures

PrimaryChange From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16

The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16-8.9 (-10.96 to -6.90)-9.2 (-11.23 to -7.23)-11.8 (-13.84 to -9.75)-10.1 (-12.10 to -8.10)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.834 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and Kellgren-Lawrence (K-L) grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.3 · 95% CI -3.13 to 2.53
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.05 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2.9 · 95% CI -5.73 to 0.01
  • ABT-981 200 mg · ANCOVA · p = 0.415 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -1.2 · 95% CI -4.00 to 1.66
PrimaryChange From Baseline in Quantitative Synovitis of the Index Knee at Week 26

Change in synovitis of the index knee was evaluated using quantitative magnetic resonance imaging (MRI) measurements. MRI quantitative synovitis of the index knee was defined by mean synovial membrane thickness.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · mm
Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26
mmPlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26-0.05 (-0.107 to 0.011)0.01 (-0.045 to 0.068)-0.08 (-0.134 to -0.016)0.01 (-0.047 to 0.067)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.145 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.06 · 95% CI -0.021 to 0.141
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.52 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.03 · 95% CI -0.11 to 0.056
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.159 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.06 · 95% CI -0.023 to 0.139
PrimaryChange From Baseline in Effusion Volume of the Index Knee at Week 26
Time frame:
Baseline, Week 26
Reported as:
Least squares mean · mL
Change From Baseline in Effusion Volume of the Index Knee at Week 26
mLPlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in Effusion Volume of the Index Knee at Week 260.03 (-2.498 to 2.562)0.26 (-2.113 to 2.624)-1.04 (-3.421 to 1.347)-1.49 (-3.868 to 0.898)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.897 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.22 · 95% CI -3.193 to 3.642
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.542 (P-value for test of difference between ABT-981 100 dose group and Placebo at each post-baseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -1.07 · 95% CI -4.515 to 2.377
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.385 (P-value for test of difference between ABT-981 200 dose group and Placebo at each post-baseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -1.52 · 95% CI -4.95 to 1.916
PrimaryChange From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26

Semi-quantitative synovitis/effusion volume WORMS scores were scored as normal (0), \< 33% of maximum estimated distention (1), 33% - 66% of maximum estimated distention (2), or \> 66% of maximum estimated distention (3).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 260.07 (-0.057 to 0.193)-0.01 (-0.130 to 0.113)-0.08 (-0.205 to 0.043)-0.07 (-0.196 to 0.048)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.384 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.08 · 95% CI -0.249 to 0.096
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.095 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.15 · 95% CI -0.324 to 0.026
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.106 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.14 · 95% CI -0.314 to 0.03
SecondaryChange From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16

The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16-28.7 (-35.30 to -22.15)-29.8 (-36.27 to -23.32)-36.3 (-42.90 to -29.69)-32.1 (-38.64 to -25.63)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.818 (P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -1.1 · 95% CI -10.22 to 8.08
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.109 (P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -7.6 · 95% CI -16.83 to 1.69
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.465 (P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -3.4 · 95% CI -12.58 to 5.76
SecondaryChange From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26

The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26-29.7 (-36.61 to -22.75)-31.8 (-38.62 to -24.98)-38.9 (-45.83 to -31.92)-36.9 (-43.71 to -30.00)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.666 (P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2.1 · 95% CI -11.76 to 7.52
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.065 (P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -9.2 · 95% CI -18.95 to 0.56
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.145 (P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -7.2 · 95% CI -16.84 to 2.49
SecondaryChange From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52

The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52-32.9 (-40.66 to -25.12)-36.1 (-43.76 to -28.46)-38.7 (-46.52 to -30.92)-39.7 (-47.37 to -32.00)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.558 (P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -3.2 · 95% CI -14.03 to 7.59
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.295 (P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -5.8 · 95% CI -16.77 to 5.11
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.218 (P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -6.8 · 95% CI -17.63 to 4.04
SecondaryChange From Baseline in WOMAC Pain Scores of the Index Knee at Week 26

The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26-9.2 (-11.29 to -7.07)-9.8 (-11.90 to -7.75)-11.9 (-13.99 to -9.76)-11.6 (-13.65 to -9.51)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.664 (P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.6 · 95% CI -3.58 to 2.28
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.075 (P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2.7 · 95% CI -5.67 to 0.28
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.107 (P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2.4 · 95% CI -5.33 to 0.52
SecondaryChange From Baseline in WOMAC Pain Scores of the Index Knee at Week 52

The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52-10.0 (-12.24 to -7.68)-11.0 (-13.29 to -8.80)-12.1 (-14.42 to -9.84)-12.2 (-14.49 to -10.0)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.5 (P-value for test of difference between ABT-981 25 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.5 · 95% CI -4.26 to 2.08
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.186 (P-value for test of difference between ABT-981 100 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2.2 · 95% CI -5.39 to 1.05
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.157 (P-value for test of difference between ABT-981 200 mg dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment, age, K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2.3 · 95% CI -5.46 to 0.88
SecondaryChange From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26

BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 260.1 (-0.24 to 0.43)0.3 (0.01 to 0.65)-0.0 (-0.37 to 0.29)0.1 (-0.22 to 0.43)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.319 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.2 · 95% CI -0.23 to 0.69
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.564 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.1 · 95% CI -0.6 to 0.33
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.966 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0 · 95% CI -0.45 to 0.47
SecondaryChange From Baseline in Global Total BML Score of the Index Knee MRI at Week 52

BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 520.1 (-0.34 to 0.48)0.2 (-0.16 to 0.60)0.1 (-0.30 to 0.48)0.0 (-0.36 to 0.39)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.602 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.1 · 95% CI -0.41 to 0.7
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.953 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0 · 95% CI -0.55 to 0.58
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.83 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.1 · 95% CI -0.61 to 0.49
SecondaryChange From Baseline in Index Knee Intermittent and Constant Osteoarthritis Pain (ICOAP) Scores at Week 16

The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Index Knee Intermittent and Constant Osteoarthritis Pain (ICOAP) Scores at Week 16
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Intermittent Pain-20.2 (-24.32 to -16.08)-19.5 (-23.40 to -15.58)-21.3 (-25.40 to -17.26)-18.8 (-22.92 to -14.71)
Constant Pain-18.6 (-22.88 to -14.33)-17.7 (-21.73 to -13.62)-24.2 (-28.39 to -19.94)-20.0 (-24.24 to -15.72)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.804 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.7 · 95% CI -4.91 to 6.33
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.699 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -1.1 · 95% CI -6.9 to 4.63
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.636 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 1.4 · 95% CI -4.37 to 7.14
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.756 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.9 · 95% CI -4.91 to 6.76
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.068 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -5.6 · 95% CI -11.55 to 0.42
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.649 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -1.4 · 95% CI -7.34 to 4.58
SecondaryChange From Baseline in Index Knee ICOAP Scores at Week 26

The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in Index Knee ICOAP Scores at Week 26
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Intermittent Pain-18.7 (-23.21 to -14.21)-19.7 (-23.99 to -15.42)-21.3 (-25.66 to -16.98)-21.7 (-26.11 to -17.38)
Constant Pain-19.6 (-24.22 to -14.96)-18.8 (-23.26 to -14.42)-21.6 (-26.05 to -17.08)-22.1 (-26.61 to -17.61)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.75 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -1 · 95% CI -7.14 to 5.14
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.409 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2.6 · 95% CI -8.82 to 3.6
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.338 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -3 · 95% CI -9.24 to 3.18
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.817 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.7 · 95% CI -5.59 to 7.08
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.544 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2 · 95% CI -8.37 to 4.43
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.437 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2.5 · 95% CI -8.91 to 3.86
SecondaryChange From Baseline in Index Knee ICOAP Scores at Week 52

The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Index Knee ICOAP Scores at Week 52
score on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Intermittent Pain-23.2 (-28.51 to -17.83)-25.4 (-30.21 to -20.51)-23.6 (-28.53 to -18.64)-27.2 (-32.19 to -22.14)
Constant Pain-20.6 (-25.93 to -15.21)-21.8 (-26.70 to -16.94)-25.2 (-30.14 to -20.17)-29.7 (-34.78 to -24.66)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.545 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -2.2 · 95% CI -9.31 to 4.92
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.909 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.4 · 95% CI -7.65 to 6.81
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.278 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -4.0 · 95% CI -11.23 to 3.25
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.732 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -1.2 · 95% CI -8.42 to 5.92
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.216 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -4.6 · 95% CI -11.86 to 2.69
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.014 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -9.2 · 95% CI -16.42 to -1.88
SecondaryChange From Baseline In Index Knee Pain Intensity at Week 16

The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline In Index Knee Pain Intensity at Week 16
units on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
7-Day Recall Period-2.4 (-2.86 to -1.97)-2.4 (-2.79 to -1.95)-2.7 (-3.09 to -2.22)-2.1 (-2.55 to -1.67)
Activity Pain-2.3 (-2.85 to -1.82)-2.4 (-2.85 to -1.87)-2.7 (-3.19 to -2.17)-2.1 (-2.59 to -1.56)
Performance Pain (Before)-2.4 (-2.82 to -1.89)-2.1 (-2.58 to -1.70)-2.5 (-2.97 to -2.06)-2.1 (-2.52 to -1.60)
Performance Pain (After)-2.6 (-3.07 to -2.11)-2.4 (-2.90 to -2.00)-2.7 (-3.16 to -2.22)-2.3 (-2.77 to -1.82)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.874 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.0 · 95% CI -0.56 to 0.66
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.451 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.2 · 95% CI -0.86 to 0.38
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.331 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.3 · 95% CI -0.31 to 0.93
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.932 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.0 · 95% CI -0.73 to 0.67
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.344 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.3 · 95% CI -1.07 to 0.37
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.489 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.3 · 95% CI -0.47 to 0.97
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.498 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.2 · 95% CI -0.42 to 0.85
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.637 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.2 · 95% CI -0.8 to 0.49
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.367 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.3 · 95% CI -0.35 to 0.94
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.67 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.1 · 95% CI -0.51 to 0.79
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.776 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.1 · 95% CI -0.76 to 0.57
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.387 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.3 · 95% CI -0.37 to 0.96
SecondaryChange From Baseline In Index Knee Pain Intensity at Week 26

The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline In Index Knee Pain Intensity at Week 26
units on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
7-Day Recall Period-2.2 (-2.76 to -1.73)-2.4 (-2.89 to -1.91)-2.8 (-3.29 to -2.31)-2.5 (-2.98 to -1.99)
Activity Pain-2.5 (-3.07 to -1.91)-2.5 (-3.10 to -1.99)-2.8 (-3.37 to -2.25)-2.5 (-3.10 to -1.97)
Performance Pain (Before)-2.2 (-2.72 to -1.70)-2.2 (-2.68 to -1.71)-2.6 (-3.13 to -2.16)-2.7 (-3.15 to -2.17)
Performance Pain (After)-2.5 (-3.01 to -1.98)-2.4 (-2.90 to -1.92)-3.0 (-3.53 to -2.54)-2.6 (-3.13 to -2.13)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.661 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.2 · 95% CI -0.86 to 0.54
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.122 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.6 · 95% CI -1.26 to 0.15
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.507 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.2 · 95% CI -0.94 to 0.47
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.892 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.1 · 95% CI -0.85 to 0.74
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.433 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.3 · 95% CI -1.12 to 0.48
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.92 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.0 · 95% CI -0.84 to 0.76
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.957 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.0 · 95% CI -0.68 to 0.71
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.222 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.4 · 95% CI -1.13 to 0.26
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.209 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.4 · 95% CI -1.15 to 0.25
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.813 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.1 · 95% CI -0.62 to 0.79
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.135 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.5 · 95% CI -1.25 to 0.17
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.679 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.1 · 95% CI -0.85 to 0.57
SecondaryChange From Baseline In Index Knee Pain Intensity at Week 52

The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline In Index Knee Pain Intensity at Week 52
units on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
7-Day Recall Period-2.9 (-3.51 to -2.35)-2.9 (-3.45 to -2.39)-2.9 (-3.43 to -2.35)-3.1 (-3.65 to -2.56)
Activity Pain-2.8 (-3.48 to -2.16)-3.0 (-3.64 to -2.43)-3.2 (-3.77 to -2.55)-3.0 (-3.65 to -2.40)
Performance Pain (Before)-2.6 (-3.14 to -2.03)-2.7 (-3.24 to -2.23)-3.0 (-3.51 to -2.49)-2.9 (-3.46 to -2.41)
Performance Pain (After)-2.9 (-3.47 to -2.33)-3.0 (-3.53 to -2.50)-3.4 (-3.90 to -2.86)-3.2 (-3.69 to -2.62)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.978 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.0 · 95% CI -0.76 to 0.79
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.925 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.0 · 95% CI -0.75 to 0.82
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.659 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.2 · 95% CI -0.96 to 0.61
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.633 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.2 · 95% CI -1.1 to 0.67
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.46 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.3 · 95% CI -1.23 to 0.56
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.663 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.2 · 95% CI -1.1 to 0.7
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.696 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.1 · 95% CI -0.89 to 0.59
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.278 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.4 · 95% CI -1.16 to 0.34
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.357 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.4 · 95% CI -1.1 to 0.4
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.761 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.1 · 95% CI -0.87 to 0.64
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.218 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.5 · 95% CI -1.02 to 0.51
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.513 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.3 · 95% CI -1.02 to 0.51
SecondaryChange From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16

The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16
units on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16-2.5 (-2.94 to -2.01)-2.4 (-2.80 to -1.92)-2.9 (-3.34 to -2.42)-2.6 (-3.08 to -2.15)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.728 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.1 · 95% CI -0.52 to 0.75
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.219 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.4 · 95% CI -1.06 to 0.24
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.673 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.1 · 95% CI -0.79 to 0.51
SecondaryChange From Baseline in PGA of Arthritis of the Index Knee at Week 26

The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in PGA of Arthritis of the Index Knee at Week 26
units on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in PGA of Arthritis of the Index Knee at Week 26-2.4 (-2.96 to -1.91)-2.4 (-2.94 to -1.94)-3.0 (-3.48 to -2.47)-2.7 (-3.18 to -2.16)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.984 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.0 · 95% CI -0.73 to 0.71
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.145 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.5 · 95% CI -1.26 to 0.19
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.527 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.2 · 95% CI -0.96 to 0.49
SecondaryChange From Baseline in PGA of Arthritis of the Index Knee at Week 52

The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in PGA of Arthritis of the Index Knee at Week 52
units on a scalePlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Change From Baseline in PGA of Arthritis of the Index Knee at Week 52-3.0 (-3.62 to -2.44)-2.9 (-3.48 to -2.41)-3.2 (-3.71 to -2.62)-3.5 (-4.01 to -2.89)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.836 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.1 · 95% CI -0.71 to 0.87
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.738 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.1 · 95% CI -0.94 to 0.66
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.3 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.4 · 95% CI -1.22 to 0.38
SecondaryChange From Baseline in Cartilage Volume of the Index Knee at Week 26

Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · mm^3
Change From Baseline in Cartilage Volume of the Index Knee at Week 26
mm^3PlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Global Knee-326.0 (-400.83 to -251.13)-325.5 (-397.10 to -253.83)-322.4 (-400.20 to -244.61)-359.0 (-429.72 to -288.35)
Medial Central Condyle + Plateau-59.1 (-83.12 to -35.10)-54.9 (-77.83 to -31.90)-50.1 (-75.13 to -25.07)-57.5 (-80.12 to -34.88)
Medial Condyle + Plateau-128.6 (-166.76 to -90.50)-126.5 (-163.03 to -90.02)-124.5 (-164.13 to -84.86)-114.9 (-150.86 to -78.90)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.992 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.5 · 95% CI -101.59 to 102.62
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.948 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 3.6 · 95% CI -103.95 to 111.10
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.523 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -33.1 · 95% CI -134.76 to 68.65
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.799 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 4.2 · 95% CI -28.47 to 36.95
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.609 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 9.0 · 95% CI -25.62 to 43.64
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.923 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 1.6 · 95% CI -30.97 to 34.19
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.937 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 2.1 · 95% CI -49.88 to 54.08
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.882 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 4.1 · 95% CI -50.68 to 58.95
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.602 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 13.8 · 95% CI -38.05 to 65.55
SecondaryChange From Baseline in Cartilage Volume of the Index Knee at Week 52

Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · mm^3
Change From Baseline in Cartilage Volume of the Index Knee at Week 52
mm^3PlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Global Knee-557.0 (-659.86 to -454.10)-598.7 (-694.66 to -502.76)-554.3 (-654.92 to -453.60)-583.1 (-678.88 to -487.23)
Medial Central Condyle + Plateau-101.2 (-134.56 to -67.79)-126.3 (-157.5 to -95.09)-90.1 (-122.89 to -57.29)-113.0 (-144.08 to -81.84)
Medial Condyle + Plateau-214.7 (-273.77 to -155.64)-255.0 (-310.03 to -199.97)-190.3 (-248.05 to -132.51)-242.8 (-297.71 to -187.86)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.554 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -41.7 · 95% CI -180.49 to 97.04
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.97 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 2.7 · 95% CI -140.86 to 146.31
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.713 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -26.1 · 95% CI -165.47 to 113.32
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.272 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -25.1 · 95% CI -70.12 to 19.88
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.64 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 11.1 · 95% CI -35.63 to 57.8
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.608 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -11.8 · 95% CI -56.94 to 33.38
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.319 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -40.3 · 95% CI -119.88 to 39.3
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.56 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 24.4 · 95% CI -58.05 to 106.91
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.489 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -28.1 · 95% CI -107.97 to 51.82
SecondaryChange From Baseline in Cartilage Thickness of the Index Knee at Week 26

Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · mm
Change From Baseline in Cartilage Thickness of the Index Knee at Week 26
mmPlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Global Knee-0.047 (-0.058 to -0.036)-0.047 (-0.058 to -0.037)-0.048 (-0.059 to -0.037)-0.052 (-0.062 to -0.041)
Medial Central Condyle + Plateau-0.085 (-0.122 to -0.048)-0.077 (-0.113 to -0.042)-0.074 (-0.113 to -0.036)-0.076 (-0.111 to -0.041)
Medial Condyle + Plateau-0.046 (-0.060 to -0.031)-0.045 (-0.059 to -0.031)-0.047 (-0.062 to -0.032)-0.044 (-0.058 to -0.031)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.972 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.0 · 95% CI -0.015 to 0.015
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.929 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.001 · 95% CI -0.017 to 0.015
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.543 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.005 · 95% CI -0.02 to 0.01
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.752 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.008 · 95% CI -0.043 to 0.059
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.691 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.011 · 95% CI -0.042 to 0.064
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.71 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.01 · 95% CI -0.041 to 0.06
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.965 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.0 · 95% CI -0.019 to 0.02
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.885 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.002 · 95% CI -0.022 to 0.019
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.887 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.001 · 95% CI -0.018 to 0.021
SecondaryChange From Baseline in Cartilage Thickness of the Index Knee at Week 52

Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · mm
Change From Baseline in Cartilage Thickness of the Index Knee at Week 52
mmPlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Global Knee-0.081 (-0.095 to -0.066)-0.085 (-0.099 to -0.072)-0.081 (-0.095 to -0.067)-0.083 (-0.097 to -0.070)
Medial Central Condyle + Plateau-0.136 (-0.187 to -0.084)-0.176 (-0.224 to -0.127)-0.113 (-0.163 to -0.062)-0.141 (-0.190 to -0.093)
Medial Condyle + Plateau-0.084 (-0.106 to -0.063)-0.096 (-0.117 to -0.076)-0.073 (-0.094 to -0.052)-0.087 (-0.107 to -0.067)
Statistical analysis
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.619 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.005 · 95% CI -0.024 to 0.014
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.952 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.001 · 95% CI -0.02 to 0.019
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.765 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.003 · 95% CI -0.022 to 0.016
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.258 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.04 · 95% CI -0.11 to 0.03
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.535 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.023 · 95% CI -0.049 to 0.094
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.866 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.006 · 95% CI -0.076 to 0.064
  • Placebo vs ABT-981 25 mg · ANCOVA · p = 0.413 (P-value for test of difference between ABT-981 25 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.012 · 95% CI -0.041 to 0.017
  • Placebo vs ABT-981 100 mg · ANCOVA · p = 0.445 (P-value for test of difference between ABT-981 100 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: 0.012 · 95% CI -0.018 to 0.042
  • Placebo vs ABT-981 200 mg · ANCOVA · p = 0.835 (P-value for test of difference between ABT-981 200 mg dose group and Placebo at each postbaseline time point was from an ANCOVA model with treatment, age, and K-L grade as the main factors and baseline as a covariate.) · Ls mean difference: -0.003 · 95% CI -0.032 to 0.026
SecondaryOutcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16

Percentage of participants classified as OMERACT-OARSI responders at Week 16. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16
percentage of participantsPlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 1660.0 (49.6 to 70.4)67.0 (57.2 to 76.9)72.6 (63.1 to 82.2)65.5 (55.5 to 75.5)
Statistical analysis
  • Placebo vs ABT-981 25 mg · Cochran-Mantel-Haenszel · p = 0.311 (P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.) · Response rate difference: 7.0 · 95% CI -7.3 to 21.4
  • Placebo vs ABT-981 100 mg · Cochran-Mantel-Haenszel · p = 0.435 (P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.) · Response rate difference: 5.5 · 95% CI -8.9 to 19.9
  • Placebo vs ABT-981 200 mg · Cochran-Mantel-Haenszel · p = 0.435 (P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.) · Response rate difference: 5.5 · 95% CI -8.9 to 19.9
SecondaryOutcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26

Percentage of participants classified as OMERACT-OARSI responders at Week 26. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26
percentage of participantsPlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 2662.4 (52.1 to 72.7)64.8 (54.8 to 74.8)66.7 (56.6 to 76.7)72.7 (63.4 to 82.0)
Statistical analysis
  • Placebo vs ABT-981 25 mg · Cochran-Mantel-Haenszel · p = 0.744 (P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.) · Response rate difference: 2.4 · 95% CI -11.9 to 16.8
  • Placebo vs ABT-981 100 mg · Cochran-Mantel-Haenszel · p = 0.581 (P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.) · Response rate difference: 4.3 · 95% CI -10.1 to 18.7
  • Placebo vs ABT-981 200 mg · Cochran-Mantel-Haenszel · p = 0.146 (P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.) · Response rate difference: 10.4 · 95% CI -3.5 to 24.3
SecondaryOutcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52

Percentage of participants classified as OMERACT-OARSI responders at Week 52. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52
percentage of participantsPlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 5270.6 (60.9 to 80.3)69.3 (59.7 to 79.0)71.4 (61.8 to 81.1)72.7 (63.4 to 82.0)
Statistical analysis
  • Placebo vs ABT-981 25 mg · Cochran-Mantel-Haenszel · p = 0.824 (P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.) · Response rate difference: -1.3 · 95% CI -14.9 to 12.4
  • Placebo vs ABT-981 100 mg · Cochran-Mantel-Haenszel · p = 0.964 (P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.) · Response rate difference: 0.8 · 95% CI -12.8 to 14.5
  • Placebo vs ABT-981 200 mg · Cochran-Mantel-Haenszel · p = 0.763 (P-value for test of difference between each ABT-981 dose group and Placebo was from a Cochran-Mantel-Haenszel test using age group and K-L grade as stratification factors.) · Response rate difference: 2.1 · 95% CI -11.3 to 15.6

Adverse events

Collected over up to Week 52 (or last dose of study drug) plus 70 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—8/85 (9.4%)66/85 (77.6%)
ABT-981 25 mg—11/89 (12.4%)63/89 (70.8%)
ABT-981 100 mg—8/85 (9.4%)65/85 (76.5%)
ABT-981 200 mg—4/88 (4.5%)75/88 (85.2%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventPlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
FALLInjury, poisoning and procedural complications2/850/891/850/88
ENTEROCOLITISGastrointestinal disorders1/850/890/850/88
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders1/850/890/850/88
CHOLECYSTITISHepatobiliary disorders0/851/891/850/88
LIVER DISORDERHepatobiliary disorders1/850/890/850/88
DIVERTICULITISInfections and infestations1/850/890/850/88
PNEUMONIAInfections and infestations0/850/891/850/88
URINARY TRACT INFECTIONInfections and infestations1/850/890/850/88
ANKLE FRACTUREInjury, poisoning and procedural complications1/851/890/850/88
CERVICAL VERTEBRAL FRACTUREInjury, poisoning and procedural complications0/850/891/850/88
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mg
HEADACHENervous system disorders22/8514/8914/8521/88
NEUTROPENIABlood and lymphatic system disorders1/8512/8912/8521/88
ARTHRALGIAMusculoskeletal and connective tissue disorders16/8516/8919/8514/88
NASOPHARYNGITISInfections and infestations16/859/8913/8517/88
BACK PAINMusculoskeletal and connective tissue disorders14/858/8911/8514/88
NEUTROPHIL COUNT DECREASEDInvestigations1/853/8913/8513/88
FATIGUEGeneral disorders12/854/895/857/88
INJECTION SITE REACTIONGeneral disorders0/856/898/8512/88
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations8/858/897/8512/88
INFLUENZAInfections and infestations10/852/895/854/88

Baseline characteristics

Modified intent-to-treat population: all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mgTotal
Mean59.53 ± 8.85061.63 ± 7.54660.21 ± 8.19459.05 ± 10.27360.11 ± 8.792
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboABT-981 25 mgABT-981 100 mgABT-981 200 mgTotal
Female52635357225
Male33263231122
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Fleischmann RM, Bliddal H, Blanco FJ, Schnitzer TJ, Peterfy C, Chen S, Wang L, Feng S, Conaghan PG, Berenbaum F, Pelletier JP, Martel-Pelletier J, Vaeterlein O, Kaeley GS, Liu W, Kosloski MP, Levy G, Zhang L, Medema JK, Levesque MC. A Phase II Trial of Lutikizumab, an Anti-Interleukin-1alpha/beta Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis Rheumatol. 2019 Jul;71(7):1056-1069. doi: 10.1002/art.40840. Epub 2019 Jun 7. PubMed 30653843 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jun 2016, 24 months.

Results were first posted in Aug 2019, 3 years 2 months after primary completion. A results delay was requested in Aug 2017.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 24 months is above that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2014
First posted
Mar 14, 2014
StartActual
Jun 4, 2014
Primary completionActual
Jun 7, 2016
CompletionActual
Dec 13, 2016
Results delay requested
Aug 25, 2017
Results first posted
Aug 28, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02087904
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 14, 2014
Start date
Jun 4, 2014
Primary completion
Jun 7, 2016
Completion
Dec 13, 2016
Results posted
Aug 28, 2019
Last update
Aug 28, 2019

Study contacts

Marc Levesque, MD
study chair · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutikizumab

Start the discussion